DGI BioTechnologies

DGI BioTechnologies, L.L.C. is a biotechnology-based research company formed in January, 1996 to develop its proprietary small molecule drug discovery platform, called Diogenesis. DGI is majority owned, and fully funded by New Brunswick Scientific Co., Inc. (NBSC). DGI utilizes 7500-square foot of newly equipped laboratory space at NBSC's main facility in Edison, New Jersey. DGI presently has employees in the fields of molecular immunology, molecular pharmacology, and structural biology. DGI will focus on the identification of novel site-directed assays and promising drug leads which regulate protein: protein interactions for license to pharmaceutical and biotechnology companies.

Activity:

- Manufacturing

Product / Technology type(s) covered:

- Bio
- Proteins
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: